CAS: 149908-53-2; 1-(((5-(4-Chlorophenyl)Furan-2-yl)Methylene)Amino)-3-(4-(4-Methylpiperazin-1-yl)Butyl)Imidazolidine-2,4-Dione

该化合物是一种化学化合物,属于抗心律剂类别,专门设计用于治疗心律不全,主要作为钾渠道阻塞剂,有助于稳定心膜膜,并通过延长行动期恢复正常节奏.Azimilide展示了独特的药理特征,既提供了抗心律特性,也提供了相对优异的副作用特征,与该类其他制剂相比,该化合物具有相对有利的副作用.该化合物已被研究过,以了解其在管理审判性纤维炎和心血管心电图方面的效力.该化合物的化学结构包括有助于其生物活动和溶液特性的具体功能组.Azimilide的动作机制涉及某些电离子渠道的选择性抑制,这对于治疗效果至关重要.尽管它在临床环境中表现出了希望,但其使用可能受到药物相互作用和对心脏功能进行仔细监测的需要的限制.

结构式图片

合成工艺路线路线简述

    Azimilide置于碳酸氢钠体系中,用 水 用作溶剂,化学反应生成阿齐利特
    参考文献:4-Oxocyclic Ureas Useful As Antiarrhythmic And Antifibrillatory Agents
    标题:4-Oxocyclic Ureas Useful As Antiarrhythmic And Antifibrillatory Agents
    摘要:本发明的新型4-氧代环脲及其药用可接受盐和酯可用作抗心律失常和抗颤荡剂,具有以下一般结构:其中(A) X为饱和或不饱和的5,6或7元杂环或碳环;(B) R选自共价键,零,杂原子,羰基,杂环环,碳环,烷基,烯基,烷氧基,烷基氨基,芳基烷基,芳氧基,酰基,酰氧基和酰氨基组成的群体;(C) Y为取代或未取代的饱和或不饱和的5,6或7元杂环环或碳环,或为零;当r为零时,X和y为融合环系统;当r为共价键时,X和y通过共价键连接为环系统;当y为零时,R为共价键,X通过r与l相结合;(D) R1,R2和r3分别选自零,Cl,F,Br,Nh2,Cf3,Oh,So3H,Ch3So2Nh,Cooh,烷氧基,烷基,烷氧羰基,羟基烷基,羧基烷基,氨基烷基,酰胺基和酰氧基组成的群体;(E) L选自烷基氨基,烯基氨基,烷基亚胺,烯基亚胺和酰胺基;其中其氮原子与4-氧代环脲基团1-位置的氮原子结合;(F) R4选自烷基,烯基,炔基,烷基酰和杂烷基的群体;(G) A为取代或未取代的饱和或不饱和的直链或支链c1-C8杂烷基;或取代或未取代的饱和或不饱和的5,6或7元杂环,A具有一个氮原子,与r4相邻;(H) R5为取代或未取代的c1或c2烷基.

    海关参考信息

    专利信息


    专利号:US-10906888-B2
    优先权日:2016-07-14
    标 题:Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme
    发明人:CASIMIRO-GARCIA AGUSTIN; STROHBACH JOSEPH WALTER; HEPWORTH DAVID; LOVERING FRANK ELDRIDGE; CHOI CHULHO; ALLAIS CHRISTOPHE PHILIPPE; WRIGHT STEPHEN WAYNE
    权利人:PFIZER
    摘要:Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

    专利号:US-10308615-B2
    优先权日:2015-05-29
    标 题:Heterocyclic compounds as inhibitors of Vanin-1 enzyme
    发明人:CASIMIRO-GARCIA AGUSTIN; CONDON JEFFREY SCOTT; FLICK ANDREW CHRISTOPHER; GOPALSAMY ARIAMALA; KIRINCICH STEVEN J; MATHIAS JOHN PAUL; STROBACH JOSEPH WALTER; XIANG JASON SHAOYUN; XING LI HUANG; WANG XIAOLUN
    权利人:PFIZER
    摘要:Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

    专利号:RU-2194706-C2
    优先权日:1998-04-29
    标题 :Method of synthesis of 1-[[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]- 3-[4-(4-methyl-1-piperazinyl)butyl]-2,4-imidazolidinedione dihydrochloride

    专利号:US-6413785-B1
    优先权日:1998-02-20
    标题:Solid phase synthesis of 1-aminohydantoins
    发明人:WILSON LAWRENCE JOSEPH; PORTLOCK DAVID EDWARD; LI MIN
    权利人:PROCTER & GAMBLE
    摘要:The subject invention involves processes for making 1-aminohydantoin compounds using a solid support resin, comprising the following steps; (a) preparing a resin-bound protected α-hydrazinyl ester; (1) by reacting the resin with an α-bromo carboxylic acid, then with a protected hydrazine; or (2) by reacting the resin with a protected α-hydrazinyl carboxylic acid; (b) preparing a resin-bound imine by removing the blocking group from the hydrazinyl moiety, then reacting the unprotected hydrazinyl moiety with an aldehyde or ketone; (c) preparing a resin-bound secondary urea: (1) by reacting the imine with p-nitrophenylchloroformate or trisphosgene, then with a primary amine; or (2) by reacting the imine with an isocyanate, and (d) preparing the 1-aminohydantoin compound by removing the secondary urea from the resin and cyclizing it.

    专利号:WO-9942450-A1
    优先权日:1998-02-20
    标题:Solid phase synthesis of 1-aminohydantoins

    专利号:EP-1056726-A1
    优先权日:1998-02-20
    标题:Solid phase synthesis of 1-aminohydantoins
    上海法默生物科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.famobiotech.com
    电话: 021-36680027👤
    📞上海法默生物科技有限公司 ⚠️参考联系方式

    销售电话:021-36680027
    邮箱:sales@famobiotech.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    摘要:Conway DS, Lip GY. New antiarrhythmic agents for atrial fibrillation. Curr Opin Investig Drugs. 2001 Jan;2(1):87–92.
    摘要:Sharma S. Antiarrhythmic drugs: present and future. J Assoc Physicians India. 2007 Apr;55 Suppl():43–6.
    参考文献:10.1016/j.jacc.2003.07.033
    摘要:Singer I, Al-Khalidi H, Niazi I, Tchou P, Simmons T, Henthorn R, Holroyde M, Brum J. Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. Journal of the American College of Cardiology. 2004 Jan;43(1):39–43. doi: 10.1016/j.jacc.2003.07.033.
    参考文献:10.1097/00005344-199312000-00006
    摘要:Black SC, Butterfield JL, Lucchesi BR. Protection Against Programmed Electrical Stimulation-Induced Ventricular Tachycardia and Sudden Cardiac Death by NE-10064, a Class III Antiarrhythmic Drug. Journal of Cardiovascular Pharmacology. 1993 Dec;22(6):810–8. doi: 10.1097/00005344-199312000-00006.
    参考文献:10.1097/00005344-199404000-00020
    摘要:McIntosh MA, Tanira M, Pacini D, Kane KA. Comparison of the Cardiac Electrophysiologic Effects of NE-10064 with Sotalol and E-4031 and Their Modification by Simulated Ischaemia. Journal of Cardiovascular Pharmacology. 1994 Apr;23(4):653–7. doi: 10.1097/00005344-199404000-00020.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知